According to these findings, Li et al. further explored that gefitinib, an EGFR inhibitor, can inhibit PD-L1 binding to other T-cell receptors in addition to lowering PD-L1 expression and can reduce EGFR-overexpressing tumor cell survivals, which makes it an excellent choice for combination therapy with anti-PD-1 antibodies [5]. Here, EGFR is linked to neoplasm.